OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B
The funding discussions point to investor interest in applying AI to make breakthroughs in life sciences.
Record details
Published: 15 July 2026
Source: TechCrunch
Category: News
Topics: Healthcare · Finance, VC & PE · Biotech
Retrieved: 15 July 2026
Related evidence
These records share source-supplied organisations, an exact publisher byline, automatic topics or regions. The reason is shown on every link; related does not mean supporting, agreeing with or verifying this record.
An OpenAI researcher is leaving to build a $2bn AI drug startup that has no name yet
The Next Web AI · 15 July 2026
AI hedge fund Situational Awareness may have sold its public portfolio, but it still has its Anthropic shares
TechCrunch · 30 July 2026
DrugGen 2: A disease-aware language model for enhancing drug discovery
HuggingFace Daily Papers · 8 July 2026
Socioeconomic Inference in LLM Medical Triage: Same Symptoms, Different ZIP Code
arXiv cs.CY · 28 July 2026
When AI Tells You What You Want to Hear: Sycophantic Behavior of Large Language Models in Dementia Care Settings
arXiv · 13 April 2026
ChatGPT Utility in Healthcare Education, Research, and Practice: Systematic Review on the Promising Perspectives and Valid Concerns
OpenAlex · 19 March 2023
How to cite this record
ethics.ai (15 July 2026), “OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B,” evidence record 10321, https://ethics.ai/record/10321 (originally published by TechCrunch).
Use and limitations
This page is a stable index and citation surface for a source record. ethics.ai did not author the underlying report and has not independently verified every claim. Automatic topics may be imperfect. For consequential use, quote and cite the original publisher.